Arrakis' oral therapies targeting disease-driving RNA in myotonic dystrophy have shown promise in preclinical studies.
Sarepta has acquired the global rights to develop ARO-DUX4 and ARO-DM1, two RNAi therapeutic candidates for types of muscular ...
Columnist Shalom Lim describes a moving performance at the Enabling Lives Festival in Singapore, an example of the power of ...
The case is reported of a young woman who began having DMD symptoms before getting pregnant, allowing her to receive genetic ...
Based on the positive findings from the Phase 1/2 study, Genethon is planning to launch Phase 3 testing of GNT0004 next year.
Columnist Robin Stemple knows his walker should help prevent falls, but it didn't work out that way on a simple maneuver to ...
Columnist Patrick Moeschen, who lives with limb-girdle muscular dystrophy, explains why controlling what he can is so ...
Couch shopping made columnist Betty Vertin discover she was focused on her three children with DMD rather than the rest of her family.